Table 3 Summary of the economic studies identified in the literature (values in US$). Results in all patients and by severity subgroups when available, drotrecogin alfa compared to placebo
Study Country (year of publication) | Incremental Cost* | Incremental * effectiveness (LYG) | ICER* All severe sepsis patients | ICER* Higher risk patients |
|---|---|---|---|---|
Manns et al. [40] Canada (2002) | - | 0.38 LYG 0.76 LYG (APACHE II ≥ 25) | $ 27,936/LYG | $ 19,726/LYG (APACHE II ≥ 25) |
Neilson et al [39] Germany (2003) | $10,533 (all patients) $11,238 LYG (≥ 2 organ dysfunctions) | 0.47 LYG 0.69 LYG (≥ 2 organ dysfunctions) | US$ 22,411/LYG (3% discounting) | $ 17,419/LYG (≥ 2 organ dysfunctions) |
Angus et al. [41] US (2003) | $16,000 (±4,200) (all patients) | 0.48 LYG (SD 0.29) (all patients) | $ 33,300/LYG | - |
Betancourt et al [38] US (2003) | $6,246 (all patients) $6,246 (≥ 2 organ dysfunctions) | 0.06 lives saved** 0.08 (≥ 2 organ dysfunctions) | $ 104,100/life saved** | $78,075/life saved (≥ 2 organ dysfunctions)** |
Fowler et al. [34] Canada (2003) | $10,745 (all patients) $15,166 (APACHE ≥ 25) | 0.68 LYG 1.4 LYG (APACHE ≥ 25) | $ 15,801/LYG | $ 10,833/LYG (APACHE ≥ 25) |
Riou França et al. [35] France (2006) | $7,545 (all patients) $7,333 (2 organ dysfunctions) | 0.64 LYG (all patients) 0.57 (2 organ dysfunctions) | $ 11,812/LYG | $12,942/LYG (2 organ dysfunctions) |
Hjelmgren et al [36] Sweden (2005) | $12,272 (all patients) $14,663 (≥ 2 organ dysfunctions) | 0.544 LYG 0.474 LYG (≥ 2 organ dysfunctions) | US$ 22,920/LYG | $ 30,853/LYG (≥ 2 organ dysfunctions) |
Davies et al. [37] UK (2005) Using PROWESS data | $9,517 | 1.12 LYG | US$ 8,533/LYG | - |
Green et al. [42] UK (2006) | $11,645 (SD $1,098) (all patients) $12,336 (SD $1,430) (≥ 2 organ dysfunctions) | 1.144 LYG (SD 0.34) 1.351 LYG (≥ 2 organ dysfunctions) | $ 10,176/LYG | $ 9,132/LYG (≥ 2 organ dysfunctions) |